NR2F1’s involvement in EMT and chemoresistance, along with ATF3’s association with heightened treatment resistance, rendered these factors pivotal in cancer progression (Fu et al., 2021; Li D. et al., 2022; Liu et al., 2023; Rodriguez-Tirado et al., 2022). Here, NR2F1 is linked to cancer.